Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Autor:
Masamichi Kurosaki, Tetsuji Uno, Kohei Shomori, Atsushi Kambe, Shinji Kondo, Yuichiro Nagao, Satoko Nakada, Makoto Sakamoto, Michiharu Tanabe
Publikováno v:
Brain Tumor Pathology. 37:165-170
Solitary fibrous tumor/hemangiopericytoma is a mesenchymal tumor that originates from a common NAB2-STAT6 fusion gene and is known to very rarely demonstrate dedifferentiation in the pattern of local recurrence or distant metastasis. Here we describe
Autor:
Kenji Takahashi, Katsuharu Kameda, Yasuo Sugita, Takuya Furuta, Koichi Higaki, Koichi Ohshima, Jun Masuoka, Yoshizo Kimura
Publikováno v:
Brain Tumor Pathology. 37:127-135
In recent years, the features of lymphomas associated with chronic inflammation, referred to as diffuse large B-cell lymphoma (DLBCL) associated with chronic inflammation (DLBCL-CI), have been elucidated. DLBCL-CI is an aggressive lymphoma occurring
Autor:
Sohsuke Yamada, Takayuki Nojima, Satoko Nakada, Hideaki Iizuka, Akihiro Shioya, Osamu Tachibana, Yasuo Sasagawa, Xin Guo, Nozomu Kurose
Publikováno v:
Brain Tumor Pathology. 36:7-13
WHO grade II/III meningiomas recur frequently and there is currently no established molecular target therapy for meningioma. No previous studies have revealed the association between receptor tyrosine kinases (RTKs) and the recurrence of meningiomas.
Autor:
Masayuki Kanamori, Toshihiro Kumabe, Yoshinari Osada, Ichiyo Shibahara, Mika Watanabe, Satoshi Miyata, Takuhiro Shoji, Yukihiko Sonoda, Ryuta Saito, Teiji Tominaga
Publikováno v:
Brain tumor pathology. 38(3)
In previous studies, isocitrate dehydrogenase (IDH) mutations were associated with tumor-associated epilepsy (TAE) and venous thromboembolism (VTE). We examined the relationship between IDH mutations in grade II/III astrocytomas and TAE/VTE according
Autor:
Jong Hee Chang, Kiyong Na, Hyo Sup Shim, Young Nyun Park, Jihwan Yoo, Se Hoon Kim, Ha Young Woo
Publikováno v:
Brain tumor pathology. 37(4)
Oncogenic gene fusions have been reported in diffuse gliomas and may serve as potential therapeutic targets. Here, using next-generation sequencing analysis (Illumina TruSight Tumor 170 panel), we analyzed a total of 356 diffuse gliomas collected fro
Autor:
Naohiro Tsuyuguchi, Masahiro Nonaka, Yuji Uematsu, Yoshinori Kodama, Tomoko Shofuda, Daisuke Sakamoto, Hideyuki Arita, Yonehiro Kanemura, Kanji Mori, Daisuke Kanematsu, Takehiro Uda, Junya Fukai, Yoshiko Okita, Masayuki Mano, Toru Umehara, Naoyuki Nakao, Ema Yoshioka, Manabu Kinoshita
Publikováno v:
Brain tumor pathology. 37(2)
Aging is a known negative prognostic factor in glioblastomas (GBM). Whether particular genetic backgrounds are a factor in poor outcomes of elderly patients with GBM warrants investigation. We aim to elucidate any differences between older and younge
Autor:
T. Setoguchi, Sana Yokoi, Miki Ohira, Makiko Itami, Hajime Kageyama, Takahiro Sugiyama, Toshihiko Iuchi, Yuzo Hasegawa, T. Sakaida
Publikováno v:
Brain tumor pathology. 35(2)
In this study, we retrospectively compared the prognostic value of the 2016 WHO classification with the former classification in 387 patients with glioma treated at our institution. According to the new classification, diagnoses included oligodendrog
Autor:
Kosuke Katayama, Hiroki Ohkuma, Noriko Kato, Akira Kurose, Kiyohide Kakuta, Akihisa Kamataki, Kaoru Ogawa, Kenichiro Asano, Toshio Fumoto
Publikováno v:
Brain tumor pathology. 35(3)
For effective implantation of carmustine (BCNU) wafers, it is important to determine the order of priority with reference to the intraoperative frozen section diagnosis of the resection margin (IOFM). The accuracy of IOFM and patterns of tumor recurr
Autor:
Joji Ishida, Toshihiko Shimizu, Kentaro Fujii, Tetsuo Oka, Kazuhiko Kurozumi, Manabu Onishi, Tomotsugu Ichikawa, Yoshihiro Otani, Isao Date, Yosuke Shimazu
Publikováno v:
Brain Tumor Pathology. 32:245-252
Recently, research efforts in identifying prognostic molecular biomarkers for malignant glioma have intensified. Cysteine-rich protein 61 (CCN1) is one of the CCN family of matricellular proteins that promotes cell growth and angiogenesis in cancers
Autor:
Mika K. Kaneko, Xing Liu, Shingo Takano, Takashi Yamamoto, Akira Matsumura, Eiichi Ishikawa, Satoshi Ogasawara, Yukinari Kato, Masayuki Noguchi, Masahide Matsuda
Publikováno v:
Brain Tumor Pathology. 32:169-175
Isocitrate dehydrogenase (IDH) mutation is a valuable prognostic marker and a tool for decision-making for glioma treatment. An algorithm for IDH mutation screening was recently proposed--it consists of a two-step process of an initial search for the